A new market research report from Kalorama Information, "Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends," says that diagnostics and treatment segments taken together are valued at more than $9 billion for 2010 with 2015 sales expected to reach $10.3 billion.
The market has grown by 3 percent year-on-year, with sales increasing from $7.9 billion in 2005. With the treatment segment struggling to maintain growth, the testing segment is likely to offset declines starting in 2012.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.